Earlier Disclosure of Blood-Based Biomarkers Enhances Diagnostic Certainty and Clinical Management in Cognitive Disorders: A Review of a Recent Randomized Clinical Trial
Early disclosure of plasma p-tau217 and NfL biomarkers significantly improves diagnostic confidence and clinical decisions in cognitive decline without increasing emotional distress, supporting their integration into routine memory clinic care.